TORONTO, May 27, 2021 (GLOBE NEWSWIRE) — Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF) (“ Field Trip“), a leader in the development and delivery of psychedelic therapies, is pleased to announce that it has received conditional approval to list its common shares and warrants on the Toronto Stock Exchange (TSX). The listing is subject to the company fulfilling certain requirements of the…

Source

Previous articleAlgernon Pharmaceuticals Highlights New Animal Study Showing Effectiveness of Psychedelic Drug DMT in Treatment of Stroke
Next articleRenowned Psychedelic Researcher, James Fadiman, PhD, Joins Wesana Health Scientific Advisory Board